Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301Antonius A. Miller, Mark J. Ratain, Daryl J. Murry et al.|Journal of Clinical Oncology|2009Cited by 207
Phase I and Pharmacokinetic Study of Erlotinib for Solid Tumors in Patients With Hepatic or Renal Dysfunction: CALGB 60101Antonius A. Miller, Mark J. Ratain, Daryl J. Murry et al.|Journal of Clinical Oncology|2007Cited by 68
The Dopamine D<sub>2</sub> Receptor Contributes to the Spheroid Formation Behavior of U87 Glioblastoma CellsJillian Weissenrieder, Raymond J. Hohl|Pharmacology|2019Cited by 45
GBM-associated mutations and altered protein expression are more common in young patientsSherise D. Ferguson, Amy B. Heimberger, Joanne Xiu et al.|Oncotarget|2016Cited by 32
Functional Evaluation of a Fluorescent Schweinfurthin: Mechanism of Cytotoxicity and Intracellular QuantificationCraig H. Kuder, Raymond J. Hohl|Molecular Pharmacology|2012Cited by 13